Esperion Q1 total revenue $65.0M (-53% Y/Y); US product revenue up 41% to $34.9M

Esperion Therapeutics, Inc.

2025-Q1 EPS reported -$0.21 revenue$64,995,000

Net loss $40.5M ($0.21 EPS loss) vs net income $61.0M ($0.36 EPS) in Q1 2024 due to prior-year milestone.
Collaboration revenue $30.1M (-73% Y/Y) on $100M milestone in Q1 2024; ex-milestone +97%.
Commercial: surpassed 1M US prescriptions; reimbursement team expanded from 5 to 15 specialists.
Pipeline: unveiled PSC candidate ESP-1336 (>$1B market); triple-combination products on track for 2027.
2025 op-ex guidance $215-235M (incl. ~$15M stock comp); cash $114.6M at quarter end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.